Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tolerability, pharmacokinetics and pharmacodynamics of etamicastat administered as multiple escalating doses in male patients with hypertension

Trial Profile

Tolerability, pharmacokinetics and pharmacodynamics of etamicastat administered as multiple escalating doses in male patients with hypertension

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 12 Jan 2014

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Etamicastat (Primary)
  • Indications Essential hypertension
  • Focus Adverse reactions; Pharmacodynamics; Pharmacogenomic; Pharmacokinetics
  • Sponsors Bial
  • Most Recent Events

    • 12 Jan 2014 New trial record
    • 29 Nov 2013 Results published in Clinical Therapeutics.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top